Creator prompt
The idea behind this presentation
Slide 1: Title Slide
Main Title: DSM-5 cross-cutting symptom measures: a step towards the future of psychiatric care?
Subtitle: A Comprehensive Review of Clinical Assessment Tools
Slide 2: Section Header
Title: Perspective
Subtext: Shifting from Categorical to Dimensional Diagnosis
Slide 3: Addressing Diagnostic Limitations
Bullet Points:
The notion that psychiatric disorders occur along dimensional continua rather than categorical entities has long been debated.
Research and clinical evidence have illustrated that a categorical diagnostic schema does not accurately reflect the full realms of clinical concerns.
In the absence of a fully dimensional diagnostic schema, the integration of dimensional assessments may be clinically useful.
Slide 4: The "Review of Mental Systems"
Bullet Points:
The self- and informant-reported versions were developed by the DSM-5 Task Force to serve as a "review of mental systems."
The measures assess the presence and severity of 12-13 psychiatric symptom domains that cut across diagnostic boundaries.
The items do not relate to any specific disorder and are not intended to be diagnostic screeners for any disorder.
Slide 5: Two-Level Operationalization
Level 1 Measure: A brief survey of domains (23-item for adults; 25-item for children/adolescents) of the presence and severity of symptoms over the past two weeks.
Level 2 Measure: Detailed assessment of specific symptom domains triggered by clinical thresholds reached during the Level 1 screening process.
Slide 6: Level 1 Symptom Domains (Table)
Adult Domains: Depression, Anger, Mania, Anxiety, Somatic Symptoms, Sleep Disturbance, Psychosis, Obsessive thoughts/behaviors, Suicidal thoughts/behaviors, Substance Use, Personality Functioning, Dissociation.
Child/Adolescent Specifics: Includes Irritability and Inattention. Rated by self (age 11-17) or Parent/Guardian (age 6-17). Memory/Cognition assessed in both.
Slide 7: Scoring and Thresholds
Highlight: 2+ (Clinical Threshold)
Details: Items are rated on a 5-point scale (0=none to 4=severe). A score of 2 (mild/several days) triggers a more detailed Level 2 assessment.
Important Note: Substance use, suicidal ideation, and psychosis trigger further assessment at any score of 1 or greater.
Slide 8: Assessment Advantages
Bullet Points:
Ο Easy to administer, score, and interpret, especially in electronic form.
Self-administered format facilitates patient engagement in their own assessment and care.
Provides a standardized way to communicate about comorbidity, remission, and recovery.
Slide 9: Detailed Assessment & Utility
Level 2 Measures: Inquire about the presence and severity of symptoms within pure psychiatric domains during the past seven days (e.g., the Altman Mania Scale).
Field Testing: Demonstrated mostly good-to-excellent test-retest reliabilities and strong clinical utility from patient perspectives.
Slide 10: Potential for Growth
Transdiagnostic Identification: Allows for identification of heterogeneity within diagnoses, important for future research and understanding.
RDOC Integration: Aligns with the Research Domain Criteria (RDoC) to better integrate basic science and neurobiology into assessment.
Ο Systemic Shift: Offers an opportunity to consider research needed to maximize clinical potential and tailor patient profiles over time.
Slide 11: Conclusions
Summary:
Efforts to include a standardized battery of dimensional measures represent an important step in moving the field away from a rigid, categorical conceptualization of psychopathology.
These assessments may offer a glimpse into what the future of psychiatric care will look like, moving towards a more accurate and fully informed understanding of mental disorders.
Slide 1: Title Slide
Main Title: DSM-5 cross-cutting symptom measures: a step towards the future of psychiatric care?
Subtitle: A Comprehensive Review of Clinical Assessment Tools
Slide 2: Section Header
Title: Perspective
Subtext: Shifting from Categorical to Dimensional Diagnosis
Slide 3: Addressing Diagnostic Limitations
Bullet Points:
The notion that psychiatric disorders occur along dimensional continua rather than categorical entities has long been debated.
Research and clinical evidence have illustrated that a categorical diagnostic schema does not accurately reflect the full realms of clinical concerns.
In the absence of a fully dimensional diagnostic schema, the integration of dimensional assessments may be clinically useful.
Slide 4: The "Review of Mental Systems"
Bullet Points:
The self- and informant-reported versions were developed by the DSM-5 Task Force to serve as a "review of mental systems."
The measures assess the presence and severity of 12-13 psychiatric symptom domains that cut across diagnostic boundaries.
The items do not relate to any specific disorder and are not intended to be diagnostic screeners for any disorder.
Slide 5: Two-Level Operationalization
Level 1 Measure: A brief survey of domains (23-item for adults; 25-item for children/adolescents) of the presence and severity of symptoms over the past two weeks.
Level 2 Measure: Detailed assessment of specific symptom domains triggered by clinical thresholds reached during the Level 1 screening process.
Slide 6: Level 1 Symptom Domains (Table)
Adult Domains: Depression, Anger, Mania, Anxiety, Somatic Symptoms, Sleep Disturbance, Psychosis, Obsessive thoughts/behaviors, Suicidal thoughts/behaviors, Substance Use, Personality Functioning, Dissociation.
Child/Adolescent Specifics: Includes Irritability and Inattention. Rated by self (age 11-17) or Parent/Guardian (age 6-17). Memory/Cognition assessed in both.
Slide 7: Scoring and Thresholds
Highlight: 2+ (Clinical Threshold)
Details: Items are rated on a 5-point scale (0=none to 4=severe). A score of 2 (mild/several days) triggers a more detailed Level 2 assessment.
Important Note: Substance use, suicidal ideation, and psychosis trigger further assessment at any score of 1 or greater.
Slide 8: Assessment Advantages
Bullet Points:
Ο Easy to administer, score, and interpret, especially in electronic form.
Self-administered format facilitates patient engagement in their own assessment and care.
Provides a standardized way to communicate about comorbidity, remission, and recovery.
Slide 9: Detailed Assessment & Utility
Level 2 Measures: Inquire about the presence and severity of symptoms within pure psychiatric domains during the past seven days (e.g., the Altman Mania Scale).
Field Testing: Demonstrated mostly good-to-excellent test-retest reliabilities and strong clinical utility from patient perspectives.
Slide 10: Potential for Growth
Transdiagnostic Identification: Allows for identification of heterogeneity within diagnoses, important for future research and understanding.
RDOC Integration: Aligns with the Research Domain Criteria (RDoC) to better integrate basic science and neurobiology into assessment.
Ο Systemic Shift: Offers an opportunity to consider research needed to maximize clinical potential and tailor patient profiles over time.
Slide 11: Conclusions
Summary:
Efforts to include a standardized battery of dimensional measures represent an important step in moving the field away from a rigid, categorical conceptualization of psychopathology.
These assessments may offer a glimpse into what the future of psychiatric care will look like, moving towards a more accurate and fully informed understanding of mental disorders.
Follow Design: {"palette":["Oxford navy #0E2138 — primary text, key headers, and authoritative structures","Clinical slate blue #2C5E8A — secondary subheaders and domain category badges","Alabaster canvas #F8F9FA — clean, glare-free background surface","Soft surgical gray #E9ECEF — card backgrounds and systematic border rules","Threshold terracotta #C85A32 — clinical alert threshold indicators and Level 2 triggers","Validated sage #4D7C6F — clinical utility metrics and positive outcome highlights"],"fonts":{"Newsreader":"https://fonts.googleapis.com/css2?family=Newsreader:ital,wght@0,200..800;1,200..800&display=swap","Inter":"https://fonts.googleapis.com/css2?family=Inter:ital,wght@0,100..900;1,100..900&display=swap"},"type":"Newsreader in medium and semi-bold weights for academic and clinical inquiry titles, utilizing italic accents for medical Latinate terminology and sub-questions; Inter in regular and medium weights with tight 1.45 line-height and relaxed letter-spacing for high-legibility clinical definitions, bullet points, and multi-column domain catalogs.","layout":"A 12-column editorial medical-journal grid with generous 80px side margins, disciplined asymmetric splitting for screening tiers (Level 1 versus Level 2), and dedicated lower-third horizontal callout ribbons for scoring thresholds and immediate-escalation rules.","framework_treatment":"Crisp 1px hairline rules dividing conceptual layers, structured matrix cards with subtle rounded corners (4px), high-contrast tabular chips for symptom domain categorization, distinct severity alert pills for score >= 1 and >= 2 thresholds, and clean numbered tier progressions for diagnostic pathways.","feels_like":"A New England Journal of Medicine special clinical symposia review combined with a premium hospital diagnostic guideline"}